Amendment No. 5 dated as of August 9, 2000


 Exhibit 10.48 
  
 Confidential Materials omitted and filed separately with the 
 Securities and Exchange Commission. Asterisks denote omissions. 
  
 MDS Nordion  
 Science Advancing Health
(letterhead) 
  
 December 22, 2004 
  
 Boston Life Sciences Inc. 
 20 Newbury Street 
 Boston, Massachusetts 
 2116 USA 
  
 Dear Sirs: 
  

	Re:	Amendment #4 to Agreement between MDS Nordion Inc. 

 (now MDS Nordion, a division of MDS (Canada) Inc. 
 dated the 9th day of August, 2000 (the “Agreement”) 
  
 Reference is made to the agreement between MDS Nordion Inc. (now MDS Nordion, a division of MDS (Canada) Inc.) and Boston Life Sciences Inc. dated the 9th day of August 2000 (the “Agreement”). 
  
 In consideration of $1.00 and other valuable consideration the sufficiency of which is hereby acknowledged, the parties desire to further
amend the Agreement and extend the term. 
  

	1.	Section 16.1 of the Agreement shall be amended in its entirety and shall read as follows: 

  
 “The term of this Agreement shall commence upon the Effective Date, and unless terminated earlier pursuant to this
Agreement, shall expire on the earlier of (i) FDA granting of BLSI’s NDA with respect to Altropane for Parkinson’s Disease or (ii) December 31, 2005.” 
  

	2.	In addition to the Maximum Batch Size available for purchase as identified in Section 4.1 of the Agreement, BLSI agrees to purchase and MDS Nordion agrees to supply Altropane under
the Agreement in accordance with the terms and Batch size appearing on the face of MDS Nordion’s Quotation 2004-RQ-0400 (attached) and as amended from time to time. 

  
 All other terms and conditions in this Agreement shall remain in full force and effect. 
  
 The foregoing amendment shall be effective as of the date first written above. 






 If you agree with the foregoing, please execute this agreement in the space provided below. 
  
 Sincerely, 
  
 MDS Nordion 
  

							
	Per:	  	 /s/ Gerry Vantellingen

	  	 	  	 
	Name:	  	Gerry Vantellingen	  	 	  	 
	Title:	  	Vice President, Sales	  	 	  	 
			
	 	  	 	  	We agree this 22nd day of December,
2004.
			
	 	  	 	  	Boston Life Sciences Inc.
				
	 	  	 	  	Per:	  	 /s/ Mark Pykett


	 	  	 	  	 	  	Mark Pykett








							
	 QUOTATION
 PRO-FORMA
INVOICE
	  	FROM: MDS NORDION
				
	TO:	  	Boston Life Science Inc.	  	 DATE:
	  	2004 December 22
	 	  	20 Newbury Street	  	 	  	 
	 	  	4th Floor	  	 OUR REFERENCE:
	  	2004-RQ-0400
	 	  	Boston, MA	  	 	  	 
	 	  	02116 USA	  	 YOUR REFERENCE:
	  	 
	Attention: Mr. Richard Thorn	  	 	  	 

  

					
	 ITEM

	  	 DESCRIPTION


	1.0	  	QUOTATION FOR THE SUPPLY OF BATCHES OF ALTROPANE
FROM JANUARY 1, 2005 UNTIL DECEMBER 31, 2005.
			
	 	  	Batch Description :	  	up to 20 shippable doses of Altropane (Note 1)
			
	 	  	Price :	  	 $[**] per dose for the first 15 doses.
 Minimum price per
Batch is $[**].
 Minimum monthly total is $[**] including Batches processed in that month.

			
	 	  	Freight Charges :	  	Prepaid and invoiced at cost. AirNet is recommended and is $160 per shipment.
		
	 	  	 Note:
  
 1.      An Altropane dose contains 5mCi of I-123 as of 18:00 hrs PT the day after manufacture.
Additional product specifications are as outlined in the Agreement between BLSI and MDS Nordion which expires on September 30, 2001.
  
 2.      Minimum two (2) business days notice to cancel a Batch.
  
 3.      Clinical
sites that are to receive an Altropane dose must have their orders in by Friday Noon (ET) prior to the week where a Batch is processed.
  

	
	 UNLESS OTHERWISE STATED, PRICES DO NOT INCLUDE ANY TAXES OR DUTY.
 THIS QUOTATION IS SUBJECT TO TERMS ON THE FACE AND SECOND PAGE.



			
	 SHIPPING SCHEDULE:
 As Requested By
Customer
	  	 DELIVERY:
 F.O.B. Vancouver,
BC

	 	  	 CURRENCY:
 United States
Dollars

	 TERMS (SEE SECOND PAGE):
 Net 30
Days
	  	 QUOTATION VALID UNTIL:
 2004
December 31

	 ISSUED ON BEHALF OF MDS NORDION:
                                        
             COLYN K. STEEVES, SALES, NUCLEAR MEDICINE

		
	 MDS Nordion
 Science
Advancing Health
	  	 447 March Road, P.O. Box 13500
 Kanata, Ontario,
Canada K2K 1X8
 Tel: (613) 592-2790    Fax: (613) 592-7638








 MDS Nordion 
 Science Advancing Health (letterhead) 
  
 January 24, 2005

  
 Boston Life Sciences Inc. 
 20 Newbury Street 
 Boston, Massachusetts 
 2116 USA 
  
 Dear Sirs: 
  

	Re:	Amendment #5 to Agreement between MDS Nordion Inc. 

 (now MDS Nordion, a division of MDS (Canada) Inc. 
 dated the 9th day of August, 2000 (the “Agreement”)

  
 Reference is made to the agreement between MDS Nordion Inc, (now MDS
Nordion, a division of MDS (Canada) Inc.) and Boston Life Sciences Inc. dated the 9th day of August 2000 (the
“Agreement”) and the letter dated December 22, 2004 RE: Amendment #4. 
  
 Part 2 is further amended to read as follow: 
  

	2.	In addition to the Maximum Batch Size available for purchase as identified in Section 4.1 of the Agreement, BLSI agrees to purchase and MDS Nordion agrees to supply Altropane under
the Agreement in accordance with the terms and Batch size appearing on the face of MDS Nordion’s Quotation 2004-RQ-0400A and as amended from time to time. The Terms and Conditions on the second page of the quotation shall not apply.


  
 All other terms and conditions in this Agreement shall remain in
full force and effect. 
  
 The foregoing amendment shall be effective as of the
date first written above. 
  
 If you agree with the foregoing, please execute this
agreement in the space provided below. 
  
 Sincerely, 
  
 MDS Nordion 
  
 We agree this 24th day of January, 2005. 
  
 Boston Life Sciences Inc. 
  

							
	Per:	 	 /s/ Gerry Vantellingen

	 	        Per:	 	 /s/ Mark Pykett


	Name:	 	Gerry Vantellingen	 	 	 	Mark Pykett
	Title:	 	Vice President, Sales	 	 	 	 








							
	 QUOTATION
 PRO-FORMA
INVOICE
	  	FROM: MDS NORDION
				
	TO:	  	Boston Life Science Inc.	  	 DATE:
	  	2005 January 11
	 	  	20 Newbury Street	  	 	  	 
	 	  	8th Floor	  	 OUR REFERENCE:
	  	2004-RQ-0400 “A”
	 	  	Boston, MA	  	 	  	 
	 	  	02116 USA	  	 YOUR REFERENCE:
	  	 
	Attention: Mr. Richard Thorn	  	 	  	 

  

					
	 ITEM

	  	 DESCRIPTION


	1.0	  	 QUOTATION FOR THE SUPPLY OF BATCHES
OF ALTROPANE FROM JANUARY 1, 2005 UNTIL DECEMBER 31, 2005.
  
 REVISION “A” ISSUED TO UPDATE THE AGREEMENT FOR YEAr 2005.

			
	 	  	Batch Description :	  	up to 20 shippable doses of Altropane (Note 1)
			
	 	  	Price :	  	 $[**] per dose for the first 15 doses.
 Minimum price per
Batch is $[**].
 Minimum monthly total is $[**] including Batches processed in that month.

			
	 	  	Freight Charges :	  	Prepaid and invoiced at cost. AirNet is recommended and is $160 per shipment.
		
	 	  	 Notes:
  
 1.      An Altropane dose contains 5 mCi of I-123 as of 15:00 hrs PT., the day after manufacture.
Additional product specifications are as outlined in the Agreement between BLSI and MDS Nordion which expires on December 31, 2005.

	
	 UNLESS OTHERWISE STATED, PRICES DO NOT INCLUDE ANY TAXES OR DUTY.
 THIS QUOTATION IS SUBJECT TO TERMS ON THE FACE AND SECOND PAGE.



			
	 SHIPPING SCHEDULE:
 As Requested By
Customer
	  	 DELIVERY:
 F.O.B. Vancouver,
BC

	 	  	 CURRENCY:
 United States
Dollars

	 TERMS (SEE SECOND PAGE):
 Net 30
Days
	  	 QUOTATION VALID UNTIL:
 2005
February 28

	 ISSUED ON BEHALF OF MDS NORDION:
                                        
             COLYN K. STEEVES, SALES, NUCLEAR MEDICINE

		
	 MDS Nordion
 Science
Advancing Health
	  	 447 March Road, P.O. Box 13500
 Kanata, Ontario,
Canada K2K 1X8
 Tel: (613) 592-2790    Fax: (613) 592-7638